fentanyl has been researched along with Neuroleptic Malignant Syndrome in 3 studies
Fentanyl: A potent narcotic analgesic, abuse of which leads to habituation or addiction. It is primarily a mu-opioid agonist. Fentanyl is also used as an adjunct to general anesthetics, and as an anesthetic for induction and maintenance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1078)
fentanyl : A monocarboxylic acid amide resulting from the formal condensation of the aryl amino group of N-phenyl-1-(2-phenylethyl)piperidin-4-amine with propanoic acid.
Neuroleptic Malignant Syndrome: A potentially fatal syndrome associated primarily with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS) which are in turn associated with dopaminergic receptor blockade (see RECEPTORS, DOPAMINE) in the BASAL GANGLIA and HYPOTHALAMUS, and sympathetic dysregulation. Clinical features include diffuse MUSCLE RIGIDITY; TREMOR; high FEVER; diaphoresis; labile blood pressure; cognitive dysfunction; and autonomic disturbances. Serum CPK level elevation and a leukocytosis may also be present. (From Adams et al., Principles of Neurology, 6th ed, p1199; Psychiatr Serv 1998 Sep;49(9):1163-72)
| Excerpt | Relevance | Reference |
|---|---|---|
| "This case report describes a terminally ill patient with cancer with severe hypophosphataemia, hypocalcemia, and hypomagnesemia who developed neuroleptic malignant syndrome after administration of a combination of haloperidol and fentanyl." | 7.72 | Neuroleptic malignant syndrome after haloperidol and fentanyl infusion in a patient with cancer with severe mineral imbalance. ( Inoue, S; Morita, T; Nagayama, K; Shishido, H; Tei, Y, 2004) |
| "This case report describes a terminally ill patient with cancer with severe hypophosphataemia, hypocalcemia, and hypomagnesemia who developed neuroleptic malignant syndrome after administration of a combination of haloperidol and fentanyl." | 3.72 | Neuroleptic malignant syndrome after haloperidol and fentanyl infusion in a patient with cancer with severe mineral imbalance. ( Inoue, S; Morita, T; Nagayama, K; Shishido, H; Tei, Y, 2004) |
| "Thus, physician should consider catatonia when treating neuroleptic malignant like syndrome." | 1.36 | [Case with difficulty in differentiating between transient neuroleptic malignant syndrome and catatonia after neuroleptic analgesia]. ( Miyazaki, M; Yanagawa, Y, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Whyte, CJ | 1 |
| Rosini, JM | 1 |
| Yanagawa, Y | 1 |
| Miyazaki, M | 1 |
| Morita, T | 1 |
| Shishido, H | 1 |
| Tei, Y | 1 |
| Inoue, S | 1 |
| Nagayama, K | 1 |
3 other studies available for fentanyl and Neuroleptic Malignant Syndrome
| Article | Year |
|---|---|
Dantrolene for Treatment of Suspected Neuroleptic Malignant Syndrome.
Topics: Analgesics, Opioid; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Dantrolene; Diagnosis, D | 2018 |
[Case with difficulty in differentiating between transient neuroleptic malignant syndrome and catatonia after neuroleptic analgesia].
Topics: Adolescent; Analgesia; Anesthesia, General; Catatonia; Diagnosis, Differential; Diazepam; Droperidol | 2010 |
Neuroleptic malignant syndrome after haloperidol and fentanyl infusion in a patient with cancer with severe mineral imbalance.
Topics: Aged; Analgesics, Opioid; Dopamine Antagonists; Drug Therapy, Combination; Esophageal Neoplasms; Fen | 2004 |